ORIGINAL ARTICLEWide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension
Section snippets
Clinicians' Evaluations of NYHA/WHO Functional Class
We evaluated agreement between clinicians in their assessment of NYHA/WHO functional class by presenting information about 10 hypothetical patients with PAH (eAppendix online linked to this article). The patients described were selected to represent a range of PAH severity. Because the goal was to assess whether clinicians approached functional class in the same manner, no “gold standard” or “correct” method of determining functional class was assumed; a “correct” functional class ranking for
Clinician Participants
A total of 113 clinicians participated in the 2 evaluations (Table 1). The initial paper administration involved 28 physicians and 16 nurses; 40 physicians and 29 nurses completed the online version. An additional 6 physicians who completed the online evaluation indicated that they had also participated in the initial paper version and thus were excluded from the second analysis. All participants indicated that they were actively involved in the clinical care of patients with PAH. In the
DISCUSSION
We found a wide variation in the NYHA/WHO functional class assessments made by clinicians who care for and conduct clinical research in patients with PAH. The findings were consistent in 2 independent groups of clinicians assessed with paper and online presentations of patients with PAH. Agreement on a single functional class was not seen for any patient, and in most cases judgments spanned 2 or 3 classes. Consistent with the discrepant conclusions reached was the reported wide variation in
CONCLUSION
We observed a wide variation in the NYHA/WHO functional class assignments made by both physicians and nurses for descriptions of patients with PAH. Despite the wide use of the NYHA/WHO functional class in clinical care and as a research tool, interrater agreement may be inadequate. Our findings further suggest potential systematic differences in clinicians' approach, such that some routinely rank patients in higher (or lower) functional class than do other practitioners. Regardless of whether a
REFERENCES (21)
- et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
Chest
(2007) - et al.
Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease
Heart Lung
(2002) - et al.
Assessment of functional status in patients with cardiac disease
Heart Lung
(1998) - et al.
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology
Am Heart J
(2007) The value of approved therapies for pulmonary arterial hypertension [editorial]
Am Heart J
(2007)- et al.
Kappa coefficients in epidemiology: an appraisal of a reappraisal
J Clin Epidemiol
(1988) - et al.
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
The New York Heart Association Classes and functional status: what are we really measuring?
Heart Lung
(2006) - et al.
Classification and prognosis of pulmonary arterial hypertension
Cited by (86)
Severity of precapillary pulmonary hypertension: Predictive factor
2023, PulmonologyCitation Excerpt :Intermediate and high risks demand the association of pulmonary arterial vasodilators of different pharmacological classes, with two or three drugs.4 Therefore, risk assessment is crucial in the initial consultations by the clinician with parameters such as signs of right heart failure, progressive worsening of symptoms, syncope, and WHO/NYHA functional class.2,11,12 Complementary tests are also used, such as the 6MWT, cardiopulmonary exercise test, serum levels of brain natriuretic peptide (BNP) or its NT fraction (NT-proBNP), in addition to hemodynamic parameters during cardiac catheterization.2
Response
2023, ChestProviders’ assignment of NYHA functional class in patients with heart failure: A vignette study
2022, Heart and LungCitation Excerpt :The results of this study show an inconsistency among HF providers in the accuracy of assigning NYHA-FC, which is congruent with prior studies.6,25,26 The NYHA-FC has been called into question due to the subjectivity of the patient's reporting of their functionality and symptoms and the provider's interpretation of the reporting of symptoms.25 All of the variability with interpreting functionality can make determining NYHA-FC in patients with HF difficult especially when comorbid conditions are present which can confound presenting HF symptoms.25,27
Interobserver agreement of the anatomic and physiological classification system for adult congenital heart disease
2020, American Heart JournalCitation Excerpt :Imprecise definitions and consequently variable interpretation of the AP classification were the primary causes of disagreement between experts, as evidenced by the plurality of disagreements stemming from either unclear definitions or disagreement over definition interpretation. This aligns with studies of reliability for other clinical classifications, which find that unclear descriptions lead to decreased agreement whereas objective, quantifiable measures lead to improved agreement.17,23,24 Another source of variability was a straightforward error by a reviewer due to either misreading of the AP classification or overlooking available data; correction for these oversights improved PhyS agreement.
Predicting High-Risk Patients and High-Risk Outcomes in Heart Failure
2020, Heart Failure Clinics
Dr Taichman has received research support from Actelion for participation in REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management). Dr McGoon has received grant support from Gilead and serves on a data safety and management/clinical end point committee for Actelion. Dr Sager has served as a consultant for Actelion and Gilead and has received research support from Acetelion. Dr Palevsky has served as a consultant for Actelion and Gilead.